Saturday, March 2, 2024

CATEGORY

Regeneron

FDA Priority Review for Breakthrough Biologic Therapy: Dupixent Eyes New Frontier in COPD Treatment

Regeneron Pharmaceuticals and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application...

Eli Lilly, Novo Nordisk, Moderna and Regeneron Post Strong Quarterly Earnings Owing to Successful Development Initiatives

Eli Lilly, Novo Nordisk, Moderna, and Regeneron achieved robust quarterly earnings, attributing it to the success of their drug and pipeline development initiatives. Eli...

Latest news

Sticky Image